Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.58 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.58 |
| ▸ | CHRNG | P07510 | 2/20 | 0.58 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.58 |
| ▸ | CHRND | Q07001 | 2/20 | 0.58 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465709 | 1.00 | SLC6A2 (0.58) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL25499709 | 1.00 | SLC6A2 (0.58) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL8203173 | 0.85 | SLC6A2 (0.58) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL769582 | 0.84 | SLC6A2 (0.56) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| Hydrochloric Acid SCHEMBL5858783 | 0.83 | SLC6A2 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL13973202 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL22398923 | 0.79 | SLC6A2 (0.52) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23571741 | 0.78 | SLC6A2 (0.65) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL16698541 | 0.77 | SLC6A2 (0.50) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL634022 | 0.77 | HRH1 (0.66) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144765-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260097006-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12576078-B1 | Compounds and combinations thereof for treating neurological and psychiatric conditions | ANTECIP BIOVENTURES II LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-12569479-B2 | Bupropion as a modulator of drug activity | ANTECIP BIOVENTURES II LLC (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3220909-B2 | BUPROPION FOR MODULATING DRUG PLASMA LEVELS OF DEXTROMETORPHAN | ANTECIP BIOVENTURES II LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260007655-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250387349-A1 | COMBINATION DOSAGE FORMS AND ADMINISTRATION THEREOF | AXSOME THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250367142-A1 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | ANTECIP BIOVENTURES II LLC | 2025-12-04 | — | — | US | disclosed |
| WO-2025245375-A1 | USE OF BUPROPION AND DEXTROMETHORPHAN COMBINATIONS FOR TREATING NEUROLOGICAL DISORDERS | ANTECIP BIOVENTURES II LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12472156-B2 | Compounds and combinations thereof for treating neurological and psychiatric conditions | ANTECIP BIOVENTURES II LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20150133485-A1 | COMPOSITIONS AND METHODS OF USING THREOHYDROXYBUPROPION FOR THERAPEUTIC PURPOSES | ANTECIP BIOVENTURES II LLC | 2015-05-14 | — | — | US | disclosed |
| US-8450376-B2 | Amorphous bupropion hydrobromide and preparation thereof | GLENMARK GENERICS LTD. (IN) | 2013-05-28 | — | — | US | disclosed |
| US-8450376-B2 | Amorphous bupropion hydrobromide and preparation thereof | GLENMARK GENERICS LTD. (IN) | 2013-05-28 | — | — | US | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110105619-A1 | AMORPHOUS BUPROPION HYDROBROMIDE AND PREPARATION THEREOF | GLENMARK GENERICS LTD. (IN) | 2011-05-05 | — | — | US | disclosed |
| US-20100311727-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7763612-B2 | Therapeutic amine-arylsulfonamide conjugate compounds | ALGEBRA, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070155729-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155729-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | AADAT, AADAC, AANAT | SLC6A2 49/4885SLC6A3 21/4885CHRNA1 1655/4885 |
| US-20150133485-A1 | COMPOSITIONS AND METHODS OF USING THREOHYDROXYBUPROPION FOR THERAPEUTIC PURPOSES | DBH, COMT, THOP1 | SLC6A2 9/4885SLC6A3 4/4885CHRNA1 934/4885 |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885CHRNA1 186/4885 |
| US-20250387349-A1 | COMBINATION DOSAGE FORMS AND ADMINISTRATION THEREOF | HTT, SLC18A2, SLC6A3 | SLC6A2 4/4885SLC6A3 3/4885CHRNA1 176/4885 |
| US-20250367142-A1 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | CYP2D6, OPRM1, DBH | SLC6A2 17/4885SLC6A3 13/4885CHRNA1 183/4885 |
| US-20260144765-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | SLC6A4, SLC6A2, MAPT | SLC6A2 2/4885SLC6A3 6/4885CHRNA1 265/4885 |
| US-20260097006-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | SLC6A4, APP, HTR4 | SLC6A2 9/4885SLC6A3 27/4885CHRNA1 295/4885 |
| US-12576078-B1 | Compounds and combinations thereof for treating neurological and psychiatric conditions | SLC6A4, MAPT, APP | SLC6A2 4/4885SLC6A3 9/4885CHRNA1 248/4885 |
| US-20110105619-A1 | AMORPHOUS BUPROPION HYDROBROMIDE AND PREPARATION THEREOF | BDNF, NTRK2, HTT | SLC6A2 12/4885SLC6A3 7/4885CHRNA1 391/4885 |
| US-12472156-B2 | Compounds and combinations thereof for treating neurological and psychiatric conditions | HTR6, TARDBP, CYP2D6 | SLC6A2 6/4885SLC6A3 5/4885CHRNA1 342/4885 |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | SLC6A2 289/4885SLC6A3 874/4885CHRNA1 35/4885 |
| US-20100311727-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | AADAT, AADAC, AANAT | SLC6A2 49/4885SLC6A3 21/4885CHRNA1 1655/4885 |
| US-12569479-B2 | Bupropion as a modulator of drug activity | SLC6A4, SLC6A2, SLC18A2 | SLC6A2 2/4885SLC6A3 4/4885CHRNA1 168/4885 |
| US-20260007655-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | SLC6A4, SLC6A2, PSEN1 | SLC6A2 2/4885SLC6A3 5/4885CHRNA1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.